Prothrombin complex concentrate (Octaplex®) in patients requiring immediate reversal of oral anticoagulation

Thrombosis Research

Volumn 121, Issue 1, 2007, Pages 9-16

  Riess, Hanno B ^a   Meier Hellmann, Andreas ^b   Motsch, Johann ^c   Elias, Mazen ^d   Kursten, Friedrich W ^e   Dempfle, Carl Erik ^f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HELIOS KLINIKUM ERFURT   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d HAEMEK MEDICAL CENTER   (Israel)

^e Octapharma Pharmazeutika Produktions GmbH   (Austria)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

INR; OAT; Octaplex ; PCC; Vitamin K

Indexed keywords

BLOOD CLOTTING FACTOR; OCTAPLEX; PROTHROMBIN COMPLEX; UNCLASSIFIED DRUG; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INJECTION SITE BURNING; INTERNATIONAL NORMALIZED RATIO; INVASIVE PROCEDURE; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PARVOVIRUS; PRIORITY JOURNAL; SEPSIS; SEROCONVERSION; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PREOPERATIVE CARE; TREATMENT OUTCOME; VITAMIN K;

EID: 35648991453     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.02.009     Document Type: Article

References (24)

1. Cannegieter S.C., Rosendaal F.R., Wintzen A.R., van der Meer F.J., Vandenbroucke J.P., and Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333 (1995) 11-17
2. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 (1996) 423-428
3. van-der-Meer F.J., Rosendaal F.R., Vandenbroucke J.P., and Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153 (1993) 1557-1562
4. Baglin T. Management of warfarin (coumarin) overdose. Blood Rev 12 (1998) 91-98
5. Baker R.I., Coughlin P.B., Gallus A.S., Harper P.L., Salem H.H., and Wood E.M. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 181 (2004) 492-497
6. Dempfle C.E., and Borggrefe M. Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists. Internist (Berl) 46 (2005) 1006-1013
7. Makris M., Greaves M., Phillips W.S., Kitchen S., Rosendaal F.R., and Preston E.F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77 (1997) 477-480
8. Quick A.J. The prothrombin in hemophilia and in obstructive jaundice. J Biol Chem (1935) 10
9. PPSB. Leitlinien zur Therapie mit Blutkomponenten und Plasmaderivaten (2003), Bremen, Deutscher Ärzte-Verlag GmbH 1-293 Ref Type: Serial (Book,Monograph)
10. Koehler M., Hellstern P., Lechler E., Uberfuhr P., and Muller B.G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 80 (1998) 399-402
11. Makris M., and Watson H.G. The management of coumarin-induced over-anticoagulation annotation. Br. J. Haematol. 114 (2001) 271-280
12. Seitz R., and Dodt J. Virus safety of prothrombin complex concentrates and factor IX concentrates. Thromb. Res. 95 (1999) S19-S23
13. Biesert L., Suhartono H., Klengel R., Schmidt T., Radomski K.U., Franken T., et al. Viral safety of a prothrombin complex concentrate (OCTAPLEX): combination of solvent/detergent (SD) treatment and nanofiltration (2005) n.a. Ref Type: Abstract
14. Josic D., Hoffer L., Buchacher A., Schwinn H., Frenzel W., Biesert L., et al. Manufacturing of a prothrombin complex concentrate aiming at low thrombogenicity. Thromb Res 100 (2000) 433-441
15. CPMP. Note for guidance on plasma-derived medicinal products; CPMP/BWP/269/95, rev. 3. CPMP/BWP/269/95, rev. 3. 2001.
16. Flesland O., Seghatchian J., and Solheim B.G. The Norwegian plasma fractionation project-a 12 year clinical and economic success story. Transfus Apheresis Sci 28 (2003) 93-100
17. ®) for rapid reversal of oral anticoagulation. Thromb Res 113 (2004) 371-378
18. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 204S-233S
19. Dusel C.H., Grundmann C., Eich S., Seitz R., and Konig H. Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates. Blood Coagul Fibrinolysis 15 (2004) 405-411
20. Halbmayer W.M. Rational, high quality laboratory monitoring before, during, and after infusion of prothrombin complex concentrates. Thromb. Res. 95 (1999) S25-S30
21. Makris M. Optimisation of the prothrombin complex concentrate dose for warfarin reversal. Thromb Res 115 (2005) 451-453
22. Dager W.E., King J.H., Regalia R.C., Williamson D., Gosselin R.C., White R.H., et al. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin. Pharmacotherapy 26 8 (2006) 1091-1098
23. van-Aart L., Eijkhout H.W., Kamphuis J.S., Dam M., Schattenkerk M.E., Schouten T.J., et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res 118 3 (2006) 313-320
24. Gohlke-Bärwolf C. Anticoagulation in surgery, after hemorrhagic complications and in pregnancy. Z Kardiol 87 (1998) 56-62